Imatinib mesilato e chemioterapia combinata nel trattamento di pazienti con leucemia linfoblastica acuta positiva al cromosoma Philadelphia di nuova diagnosi
Sperimentazione internazionale di fase 3 a Philadelphia Test per la leucemia linfoblastica acuta cromosoma-positiva (Ph+ALL) Imatinib in combinazione con due diversi backbone chemioterapici citotossici
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Altro: Laboratory Biomarker Analysis
- Droga: Cyclophosphamide
- Droga: Doxorubicin
- Droga: Vincristine Sulfate
- Altro: Questionnaire Administration
- Droga: Daunorubicin Hydrochloride
- Droga: Etoposide
- Droga: Mercaptopurine
- Droga: Methylprednisolone
- Droga: Ifosfamide
- Droga: Calaspargase Pegol
- Droga: Leucovorin Calcium
- Droga: Methotrexate
- Droga: Cytarabine
- Droga: Dexamethasone
- Droga: Dexrazoxane Hydrochloride
- Biologico: Filgrastim
- Droga: Imatinib Mesylate
- Droga: Levoleucovorin
- Droga: Pegaspargase
- Droga: Prednisolone
- Droga: Therapeutic Hydrocortisone
- Droga: Thioguanine
- Procedura: Allogeneic Hematopoietic Stem Cell Transplantation
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.
SECONDARY OBJECTIVES:
I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.
III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.
IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.
V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.
VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.
EXPLORATORY OBJECTIVES:
I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.
II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.
III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.
IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.
IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.
IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.
V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.
VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.
VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).
VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.
VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.
X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.
XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.
XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.
OUTLINE:
INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.
INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.
INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.
POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.
ARM A (SR patients assigned to ARM A):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM B (SR PATIENTS ASSIGNED TO ARM B):
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM C (HR PATIENTS):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.
HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.
POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up every year for 3 years.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Riyadh, Arabia Saudita, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australia, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australia, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6008
- Princess Margaret Hospital for Children
-
Perth, Western Australia, Australia, 6009
- Perth Children's Hospital
-
-
-
-
-
Vienna, Austria, 1090
- St. Anna Children's Hospital
-
-
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgio, 3000
- Hospitals Leuven
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Prague, Cechia, 15018, 5-Motol
- University Hospital Motol
-
-
-
-
-
Santiago, Chile
- Hospital Roberto del Rio-Universidad de Chile
-
-
-
-
-
Tampere, Finlandia, 33521
- Tampere University Hospital
-
-
-
-
-
Rennes, Francia, 35203
- CHU Hopital Sud
-
-
-
-
-
Hamburg, Germania, 20246
- Universitätsklinik Eppendorf
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germania, 24105
- University Medical Center chleswig- Campus Kiel
-
-
-
-
Kowloon
-
Kowloon Bay, Kowloon, Hong Kong
- Hong Kong Children's Hospital
-
-
-
-
Central District
-
Petah Tikva, Central District, Israele, 4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
-
Monza, Italia, 20900
- Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
-
-
-
-
-
Christchurch, Nuova Zelanda, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nuova Zelanda, 1145
- Starship Children's Hospital
-
-
-
-
-
Utrecht, Olanda, 3584 CT
- Princess Máxima Center for Pediatric Oncology
-
-
-
-
-
Caguas, Porto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Porto Rico, 00926
- University Pediatric Hospital
-
San Juan, Porto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Stati Uniti, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Stati Uniti, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Stati Uniti, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Stati Uniti, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Stati Uniti, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Stati Uniti, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Stati Uniti, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90027
- Children's Hospital Los Angeles
-
Madera, California, Stati Uniti, 93636
- Valley Children's Hospital
-
Oakland, California, Stati Uniti, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Stati Uniti, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Stati Uniti, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Stati Uniti, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Stati Uniti, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Stati Uniti, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Stati Uniti, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Stati Uniti, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Stati Uniti, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Stati Uniti, 32207
- Nemours Children's Clinic-Jacksonville
-
Loxahatchee Groves, Florida, Stati Uniti, 33470
- Palms West Radiation Therapy
-
Miami, Florida, Stati Uniti, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stati Uniti, 33176
- Miami Cancer Institute
-
Orlando, Florida, Stati Uniti, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
Orlando, Florida, Stati Uniti, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Stati Uniti, 32504
- Sacred Heart Hospital
-
St. Petersburg, Florida, Stati Uniti, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Stati Uniti, 33606
- Tampa General Hospital
-
Tampa, Florida, Stati Uniti, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Stati Uniti, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Stati Uniti, 30912
- Augusta University Medical Center
-
Macon, Georgia, Stati Uniti, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Stati Uniti, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Lurie Children's Hospital-Chicago
-
Oak Lawn, Illinois, Stati Uniti, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Stati Uniti, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Stati Uniti, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Stati Uniti, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Stati Uniti, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Stati Uniti, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stati Uniti, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, Stati Uniti, 02111
- Tufts Children's Hospital
-
Worcester, Massachusetts, Stati Uniti, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Stati Uniti, 48201
- Children's Hospital of Michigan
-
Detroit, Michigan, Stati Uniti, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, Stati Uniti, 48823
- Michigan State University
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Stati Uniti, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Stati Uniti, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stati Uniti, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Stati Uniti, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Stati Uniti, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Stati Uniti, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Stati Uniti, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Stati Uniti, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Stati Uniti, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Presbyterian Hospital
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Albany Medical Center
-
Brooklyn, New York, Stati Uniti, 11219
- Maimonides Medical Center
-
Buffalo, New York, Stati Uniti, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Stati Uniti, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Stati Uniti, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10029
- Mount Sinai Hospital
-
New York, New York, Stati Uniti, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Stati Uniti, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
Stony Brook, New York, Stati Uniti, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Stati Uniti, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Stati Uniti, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Stati Uniti, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stati Uniti, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Stati Uniti, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Stati Uniti, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Stati Uniti, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stati Uniti, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Stati Uniti, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Stati Uniti, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Stati Uniti, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Stati Uniti, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Stati Uniti, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Stati Uniti, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Stati Uniti, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Stati Uniti, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Stati Uniti, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Stati Uniti, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Stati Uniti, 76104
- Cook Children's Medical Center
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Stati Uniti, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Stati Uniti, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Stati Uniti, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Stati Uniti, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Stati Uniti, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Stati Uniti, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Stati Uniti, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Stati Uniti, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Stati Uniti, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Stati Uniti, 24014
- Carilion Children's
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Stati Uniti, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Stati Uniti, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Stati Uniti, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Stati Uniti, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Children's Hospital of Wisconsin
-
-
-
-
Skåne County
-
Lund, Skåne County, Svezia, 22185
- Skane University Hospital
-
-
-
-
-
Zurich, Svizzera, CH8032
- University Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled
- For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
- In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
-
>= 1 year (365 days) and =< 21 years at ALL diagnosis
-
Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
-
ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)
-
Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
-
Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
-
Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
-
ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
-
ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
-
Direct bilirubin =< 2.0 mg/dL
-
Shortening fraction of >= 27% by echocardiogram
-
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
-
Corrected QT interval, QTc < 480 msec
- Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:
- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
-
Known history of chronic myelogenous leukemia (CML)
-
ALL developing after a previous cancer treated with cytotoxic chemotherapy
-
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
-
Down syndrome
-
Pregnancy and breast feeding
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
-
Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
-
Prior treatment with dasatinib, or any TKI other than imatinib
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A (imatinib mesylate, EsPhALL chemotherapy)
See Detailed Description |
Correlative studies Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Ancillary studies Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Given IV, SC, or IT
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given SC or IV
Altri nomi:
Given PO
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IT
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: Arm B (imatinib mesylate, COG/BFM chemotherapy)
See Detailed Description. |
Correlative studies Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Ancillary studies Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Given IV, SC, or IT
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)
See Detailed Description |
Correlative studies Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Ancillary studies Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Given IV, SC, or IT
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given SC or IV
Altri nomi:
Given PO
Altri nomi:
Given PO or IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IT
Altri nomi:
Given PO
Altri nomi:
Undergo HSCT
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Lasso di tempo: Up to 3 years
|
Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone. |
Up to 3 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Lasso di tempo: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Lasso di tempo: Up to 2 years
|
The proportion of patients who receive at least 75% of intended doses. |
Up to 2 years
|
|
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Lasso di tempo: Up to 3 years
|
Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events. |
Up to 3 years
|
|
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Lasso di tempo: Up to 3 years
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group. |
Up to 3 years
|
|
EFS of all Ph+ patients
Lasso di tempo: Up to 3 years
|
Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first. |
Up to 3 years
|
|
Overall survival (OS) of all Ph+ patients
Lasso di tempo: Up to 3 years
|
Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause. |
Up to 3 years
|
|
OS of SR Ph+ patients
Lasso di tempo: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients |
Up to 3 years
|
|
OS of SR Ph+ patients by randomization group
Lasso di tempo: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
OS of high risk Ph+ patients
Lasso di tempo: Up to 3 years
|
Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients. |
Up to 3 years
|
|
EFS of all eligibility ABL-class fusion positive ALL patients
Lasso di tempo: Up to 3 years
|
Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
|
OS of all eligibility ABL-class fusion positive ALL patients
Lasso di tempo: Up to 3 years
|
Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Lasso di tempo: Up to 2 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection. |
Up to 2 years
|
|
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Lasso di tempo: Up to 3 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm. |
Up to 3 years
|
|
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Lasso di tempo: Up to 6 months
|
For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB. |
Up to 6 months
|
|
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Lasso di tempo: Up to 3 years
|
The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored. |
Up to 3 years
|
|
MRD assessments made by IGH-TCR PCR assay and NGS assay
Lasso di tempo: Up to 3 years
|
Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected. |
Up to 3 years
|
|
IKZF1 deletions alone
Lasso di tempo: Up to 3 years
|
Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
IKZF1 deletions with other transcription factor deletions
Lasso di tempo: Up to 3 years
|
Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Other identified genetic lesions
Lasso di tempo: Up to 3 years
|
Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Frequency of p190 and p210 BCR::ABL1 fusion variants
Lasso di tempo: Up to 3 years
|
For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL. |
Up to 3 years
|
|
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Lasso di tempo: Up to 2 years
|
Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity. |
Up to 2 years
|
|
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Lasso di tempo: Up to 2 years
|
Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity. |
Up to 2 years
|
|
DFS of SR ABL-class fusion positive patients
Lasso di tempo: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Secondary and exploratory aims applied to ABL-class fusion positive patients
Lasso di tempo: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
Therapeutic impact of major secondary events
Lasso di tempo: Up to 3 years
|
Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events. |
Up to 3 years
|
|
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Lasso di tempo: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
In vivo activity
Lasso di tempo: Up to 3 years
|
Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631. |
Up to 3 years
|
|
Molecular heterogeneity
Lasso di tempo: Up to 3 years
|
Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
Cellular heterogeneity
Lasso di tempo: Up to 3 years
|
Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
CML-like phenotypes
Lasso di tempo: Up to 3 years
|
Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions. |
Up to 3 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Lewis B Silverman, Children's Oncology Group
- Investigatore principale: Andrea Biondi, EsPhALL Network/ BFM Study Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Malattie ematologiche
- Infezioni da virus del DNA
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Infezioni da virus di Epstein-Barr
- Infezioni da Herpesviridae
- Infezioni da virus tumorali
- Malattie emiche e linfatiche
- Leucemia-linfoma linfoblastico a cellule precursori
- Linfoma di Burkitt
- Leucemia-linfoma linfoblastico a cellule T precursore
- Leucemia, bifenotipica, acuta
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Terapie
- Procedure chirurgiche, operative
- Acidi nucleici, nucleotidi e nucleosidi
- Idrocarburi
- Idrocarburi, ciclici
- Fattori biologici
- Carboidrati
- Acidi carbossilici
- Alcaloidi
- Podofillotossina
- Tetraidonaftalene
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glucosidi
- Glicosidi
- Trapianto
- Amides
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Indoli
- Purine
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Derivati di benzene
- Acidi solfonici
- Acidi zolfo
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Nucleosidi
- Formyltetraidrofolates
- Tetraidrofolati
- Acido folico
- Pterins
- Pteridine
- Peptidi e proteine di segnalazione intercellulare
- Incintadienetrioli
- Amidoidrolasi
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Arabinonucleosidi
- Aminopterino
- Antracicline
- Naftaceni
- Aminoglicosidi
- Coenzimi
- Glicoproteine
- Glicoconiugati
- Gravideniones
- Incinta
- Trapianto di cellule
- Terapia a base di cellule e tessuti
- Terapia biologica
- 11-idrossicosteroidi
- Idrossicorticosteroidi
- Ormoni della corteccia surrenale
- 17-idrossicosteroidi
- Ossazine
- Acidi, carbociclico
- Benzenesolfonati
- Arilsulfonati
- Acidi arilsolfonici
- Benzoati
- Fattori stimolanti le colonie
- Fattori di crescita delle cellule ematopoietiche
- Citochine
- Benzamidi
- Piperazines
- Composti solfidrilici
- Diketopiperazines
- Imatinib mesilato
- Desametasone
- Metotrexato
- Prednisolone
- Ciclofosfamide
- Citarabina
- Etoposide
- Leucovorina
- Levoleucovorin
- Doxorubicina
- Vincristina
- Metilprednisolone
- Daunorubicina
- Idrocortisone
- Asparaginasi
- Mercaptopurina
- Dexrazoxano
- Razoxano
- Tioguanina
- Ifosfamide
- Dobesilato di calcio
- Trapianto di cellule staminali
- desametasone 21-fosfato
- Fattore stimolante le colonie di granulociti
- Filgrastim
- Calaspargase Pegol
- azathiopurina
- Merphos
- pegaspargase
- auricolare
- desametasone acetato
- Esifone
- Medrol Veriderm
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- AALL1631
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- 2017 (Sovvenzione/contratto NIH degli Stati Uniti)
- AALL1631 (Altro identificatore: CTEP)
- NCI-2016-01588 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- 2017-000705-20
- 2024-515499-12-00
- AALL1631 (Altro identificatore: Children's Oncology Group)
- 2017-000705-20 (Numero EudraCT)
- 2024-515499-12-00 (Ctis)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .